Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera®) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial

切碎 医学 美罗华 内科学 临床终点 淋巴瘤 胃肠病学 弥漫性大B细胞淋巴瘤 置信区间 CD20 随机对照试验
作者
Yuankai Shi,Qingyuan Zhang,Xiaonan Hong,Zhen Wang,Yuhuan Gao,Liqun Zou,Hong Cen,Lin Gui,Yufu Li,Jifeng Feng,Zhao Wang,Mingzhi Zhang,Chuan Jin,Weihua Zhang,Jianda Hu,Chengyun Zheng,Zhendong Zheng,Liling Zhang,Shaoshui Chen,Yunhong Huang
出处
期刊:Hematological Oncology [Wiley]
卷期号:40 (5): 930-940 被引量:5
标识
DOI:10.1002/hon.3054
摘要

This study compared the efficacy, safety and immunogenicity of ripertamab (SCT400) and rituximab (Mabthera® ) combined with CHOP as the first-line treatment for Chinese patients with CD20-positive diffuse large B cell lymphoma (DLBCL). This is a randomized, patient-blind, multicenter, active-control, non-inferiority study with parallel design. Patients were randomly (2:1) to receive ripertamab combined with CHOP (S-CHOP) or rituximab (Mabthera® ) combined with CHOP (R-CHOP) for up to 6 cycles. The primary endpoint was the Independent Review Committee (IRC) assessed objective response rate (ORR) in full analysis set (FAS) and the per protocol set (PPS). A total of 364 patients (243 in the S-CHOP and 121 in the R-CHOP groups) were enrolled in this study. In FAS, IRC-assessed ORRs were 93.8% (95% confidence interval (CI) 90.0%, 96.5%) and 94.2% (95% CI: 88.4%, 97.6%) in the S-CHOP and R-CHOP groups (p = 0.9633), respectively. The ORR difference between the two groups -0.4% (95% CI: -5.5%, 4.8%) met the pre-specified non-inferiority margin of -12%. There were no significant differences between the S-CHOP and R-CHOP groups in 1-year progression-free survival rates (81.1% vs. 83.2%, p = 0.8283), 1 year event-free survival rates (56.2% vs. 58.1%, p = 0.8005), and 3-year overall survival rates (81.0% vs. 82.8%, p = 0.7183). The results in PPS were consistent with those in FAS. The rates of treatment-emergent adverse events (TEAEs) and ≥ grade 3 TEAEs were 97.9% and 99.2%, 85.2% and 86.0% in the S-CHOP and R-CHOP groups, respectively in safety set. The percentage of anti-drug antibodies positive patients in the S-CHOP group was numerically lower than the R-CHOP group (10.9% vs. 16.0%). This study demonstrated that S-CHOP was not inferior to R-CHOP in the first-line treatment of Chinese patients with CD20-positive DLBCL in efficacy, safety and immunogenecity. S-CHOP could be an alternative first-line standard treatment regimen for this patient population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
lwm不想看文献完成签到 ,获得积分10
1秒前
3秒前
拼搏一曲发布了新的文献求助10
4秒前
CAOHOU应助科研通管家采纳,获得10
5秒前
共享精神应助科研通管家采纳,获得10
5秒前
CAOHOU应助科研通管家采纳,获得10
5秒前
SYLH应助科研通管家采纳,获得20
5秒前
乐乐应助科研通管家采纳,获得10
5秒前
汉堡包应助科研通管家采纳,获得10
5秒前
FashionBoy应助科研通管家采纳,获得10
5秒前
桐桐应助科研通管家采纳,获得10
5秒前
5秒前
深情安青应助科研通管家采纳,获得10
5秒前
CAOHOU应助科研通管家采纳,获得10
5秒前
SYLH应助科研通管家采纳,获得10
5秒前
CAOHOU应助科研通管家采纳,获得10
5秒前
Owen应助科研通管家采纳,获得10
6秒前
SYLH应助科研通管家采纳,获得10
6秒前
SYLH应助科研通管家采纳,获得10
6秒前
6秒前
酷波er应助科研通管家采纳,获得10
6秒前
wushuwen发布了新的文献求助10
6秒前
7秒前
xuan完成签到,获得积分10
8秒前
完美世界应助段一帆采纳,获得10
10秒前
少敏敏完成签到,获得积分10
12秒前
may发布了新的文献求助10
12秒前
17秒前
19秒前
兜兜关注了科研通微信公众号
19秒前
wbh完成签到,获得积分10
20秒前
太牛的GGB发布了新的文献求助10
20秒前
wbh发布了新的文献求助10
22秒前
乐乐应助may采纳,获得10
22秒前
顺利的梦菲完成签到 ,获得积分10
23秒前
777完成签到 ,获得积分10
23秒前
上官若男应助忧郁盼夏采纳,获得10
24秒前
冷艳的姿发布了新的文献求助10
25秒前
量子星尘发布了新的文献求助10
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989378
求助须知:如何正确求助?哪些是违规求助? 3531442
关于积分的说明 11254002
捐赠科研通 3270126
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173